Regueiro Miguel
Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Inflamm Bowel Dis. 2009 Oct;15(10):1583-90. doi: 10.1002/ibd.20909.
Postoperative Crohn's disease (CD) recurrence is a common occurrence after intestinal resection. Currently, the optimal management of patients who have undergone surgical resection is unknown and treatment remains subjective. Clinicians in conjunction with patients must balance the risks of recurrence against the potential risks associated with treatment. For those at very low risk of recurrence, no therapy may be needed; however, for patients at moderate risk immunomodulators should be considered. For those at highest risk of recurrence, biologic therapy, specifically antitumor necrosis factor agents, have emerged as appropriate treatment. Any postoperative management strategy should include a colonoscopy 6-12 months after surgery to identify recurrence. This review discusses current evidence for various pharmacologic approaches in the prevention of postoperative recurrence and provides guidance for clarifying patient risk.
术后克罗恩病(CD)复发是肠道切除术后的常见情况。目前,接受手术切除患者的最佳管理方法尚不清楚,治疗仍具有主观性。临床医生必须与患者共同权衡复发风险与治疗相关的潜在风险。对于复发风险极低的患者,可能无需治疗;然而,对于中度风险的患者,应考虑使用免疫调节剂。对于复发风险最高的患者,生物疗法,特别是抗肿瘤坏死因子药物,已成为合适的治疗方法。任何术后管理策略都应包括在术后6 - 12个月进行结肠镜检查以确定复发情况。本综述讨论了预防术后复发的各种药物治疗方法的现有证据,并为明确患者风险提供指导。